Key facts
- Rion Vet’s last known valuation is $74.0M (Oct 2025).
- It has raised $15.0M; the latest was Early Stage VC ($15.0M) in Oct 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Rion Vet
- ·The full record, as it builds
Funding rounds
No funding rounds for Rion Vet are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Rion Vet
Operator of a veterinary biotechnology company intended to transform animal health through first-in-class exosome biologics. The company offers proprietary exosome-based therapeutics designed to harness regenerative biology, enabling customers to access treatments that improve animal health, accelerate recovery and provide safe, effective alternatives to traditional veterinary medicines.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Rochester, MN, United States
- Ownership
- Privately Held (backing)
Rion Vet doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rion Vet shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rion Vet in its N-PORT filings yet. We sweep new filings monthly.